8-K/A: Eledon Pharmaceuticals Corrects Previous Filing Regarding Auditor Change

Eledon Pharmaceuticals amends its previous 8-K filing to correct a reference to Crowe LLP regarding the fiscal year ended December 31, 2023.

Summary

• Eledon Pharmaceuticals filed an amendment to its original 8-K report to correct a reference to Crowe LLP concerning matters related to the fiscal year ended December 31, 2023.
• The original 8-K, filed on April 7, 2025, reported the dismissal of Crowe LLP and the engagement of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Crowe LLP served as the company's independent registered public accounting firm from July 10, 2024, to April 1, 2025, and only with respect to the company's fiscal year ended December 31, 2024, and relevant interim periods within that year.
• The amendment clarifies that the reference to Crowe LLP in the original 8-K regarding the fiscal year ended December 31, 2023, was inadvertent.
• There were no disagreements with Crowe on accounting principles, practices, financial statement disclosure, or auditing scope during the fiscal year ended December 31, 2024, and the subsequent interim period.
• The audit report of Crowe on the consolidated financial statements of the company for the fiscal year ended December 31, 2024, did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles.
• The company engaged Deloitte & Touche LLP as its new independent registered public accounting firm for the company's fiscal year ending December 31, 2025, and related interim periods.
• The company did not consult Deloitte regarding the application of accounting principles or the type of audit opinion that might be rendered on the consolidated financial statements during the two most recent fiscal years and the subsequent interim period.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. The change in auditors is not inherently positive or negative, but the lack of disagreements with the previous auditor is reassuring.

Positives

• The company promptly corrected the error in the original 8-K filing.
• There were no disagreements with the previous auditor, Crowe LLP, on any accounting matters.
• The audit report from Crowe LLP for the fiscal year ended December 31, 2024, was unqualified.

Future Outlook

The company will be audited by Deloitte & Touche LLP for the fiscal year ending December 31, 2025.

Industry Context

The change in auditors is a routine event for publicly traded companies. Companies may change auditors for various reasons, including cost, expertise, or strategic alignment.

Comparison to Industry Standards

• Changing auditors is a common practice among publicly traded companies.
• Companies like Pfizer, Johnson & Johnson, and Merck have all changed auditors at some point.
• The reasons for changing auditors can vary, but it is often related to cost, expertise, or strategic alignment.

Key Dates

Keywords

auditor, Deloitte & Touche LLP, Crowe LLP, 8-K, accounting firm, Eledon Pharmaceuticals